Cargando…

P105: Decisional role of interim PET in relapsed/refractory classical Hodgkin Lymphoma treated with four begev cycles

Detalles Bibliográficos
Autores principales:	Rusconi, Chiara, Ricci, Francesca, Zilioli, Vittorio R., Marasco, Vincenzo, Calabretta, Eleonora, Guidetti, Anna, Muzi, Cristina, Mazzon, Federico, Smania, Margherita, Sollini, Martina, Meli, Erika, Rodari, Marcello, Ravano, Emanuele, Cairoli, Roberto, Corradini, Paolo, Santoro, Armando
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Relapsed/Refractory
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9621534/ http://dx.doi.org/10.1097/01.HS9.0000890988.85828.9b

Ejemplares similares

P101: Combination of immune checkpoint inhibitors with BeGEV in the treatment of patients with relapsed and refractory classical Hodgkin’s lymphoma.
por: Mangasarova, Ya.K., et al.
Publicado: (2022)

P108: Integrating baseline circulating tumor DNA with interim PET improves outcome prediction in relapsed/refractory classical Hodgkin lymphoma
por: Calabretta, Eleonora, et al.
Publicado: (2022)

P1070: DECISIONAL ROLE OF INTERIM PET IN RELAPSED/REFRACTORY CLASSICAL HODGKIN LYMPHOMA TREATED WITH BEGEV CHEMOTHERAPY AS FIRST SALVAGE
por: Rusconi, Chiara, et al.
Publicado: (2023)

T098: Brentuximab Vedotin plus ESHAP (BRESHAP) versus ESHAP in Patients with Relapsed or Refractory Classical Hodgkin’s Lymphoma. Interim Results of the BRESELIBET Prospective Clinical Trial.
por: Sureda-Balari, Anna, et al.
Publicado: (2022)

P110: Outcome of high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT) as first salvage treatment for relapsed or refractory classical Hodgkin Lymphoma (cHL) in the era of PET-adapted strategy among Italian centers
por: Viviani, Simonetta, et al.
Publicado: (2022)

P114: Very late relapses in patients with Hodgkin Lymphoma occuring ≥5 years after initial treament with chemotherapy ± radiotherapy: Treatment strategies and prognostic factors for the outcome
por: Vassilakopoulos, Theodoros P., et al.
Publicado: (2022)

P111: Phase I Trial of Brentuximab Vedotin plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

P112: Phase II Trial of Brentuximab Vedotin plus ibrutinib in Relapsed/Refractory Hodgkin Lymphoma
por: Mei, Matthew, et al.
Publicado: (2022)

P102: Comparison of Novel Salvage Regimens and Traditional salvage Chemotherapy in Relapsed and Refractory Classic Hodgkin Lymphoma
por: Shah, Harsh, et al.
Publicado: (2022)

P113: Promising results with anti-PD-1 therapy in primary refractory Hodgkin lymphoma: a single-centre report
por: Zerbi, Caterina, et al.
Publicado: (2022)

P104: Consolidation Therapy with Brentuximab Vedotin after Autologous Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Czech Republic.
por: Michalka, Jozef, et al.
Publicado: (2022)

P106: Dose intensive brentuximab vedotin for platinum resistant recurrent Hodgkin lymphoma is a feasible treatment option - a single center experience
por: Erenmalm, Axel, et al.
Publicado: (2022)

T099: High efficacy and durability of second-line therapy with pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin in the phase II study for relapsed and refractory Hodgkin lymphoma
por: Moskowitz, Alison J., et al.
Publicado: (2022)

P109: One-Day Brentuximab-Bendamustine (120mg/m2) every 21 days is a feasible and safe treatment for relapsed/refractory Hodgkin lymphoma
por: Moatti, Hannah, et al.
Publicado: (2022)

P107: Effect of Brentuximab Vedotin Addition to Chemotherapy and Prognostic Factors in Patients with Relapsed/Refractory Hodgkin Lymphoma: a Large Multi-Trial Analysis Based on Individual Patient Data
por: Driessen, Julia, et al.
Publicado: (2022)

T100: Long term Follow-up of a Phase I Study Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Research Group (E4412: Arms A-I)
por: Diefenbach, Catherine, et al.
Publicado: (2022)

P103: Comparison of PET-derived parameters in program cell death-1 inhibitor and CD30 antibody drug conjugate-based therapies in patients with advanced stage cHL: A single center experience.
por: Kamel, Serageldin, et al.
Publicado: (2022)

Current Treatment Options and the Role of Functional Status Assessment in Classical Hodgkin Lymphoma in Older Adults: A Review
por: Zilioli, Vittorio Ruggero, et al.
Publicado: (2023)

Safety and efficacy of netupitant/palonosetron and dexamethasone in classical Hodgkin’s lymphoma patients with inadequate chemotherapy-induced nausea and vomiting prophylaxis with palonosetron and dexamethasone: a single-center real-life experience
por: Zilioli, Vittorio R, et al.
Publicado: (2020)

BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience
por: Stefoni, Vittorio, et al.
Publicado: (2022)

P006: Clinical outcome of classical Hodgkin Lymphoma patients receiving systemic anti-lymphoma treatment during SARS-COV-2 positivity: Results from the chemo-covid study on behalf of fondazione italiana linfomi
por: Rusconi, Chiara, et al.
Publicado: (2022)

Multimodal imaging-based diagnostic approach for MRI-negative posterior cortex epilepsy
por: Mo, Jiajie, et al.
Publicado: (2023)

SARS-CoV-2 Interstitial Pneumonia Treated With Tocilizumab in a Patient Affected by Classical Hodgkin Lymphoma
por: Rusconi, Chiara, et al.
Publicado: (2020)

Enfermedades autoinmunes y vacunas contra la COVID-19. Toma de decisiones en escenarios de incertidumbre
por: Cairoli, Ernesto, et al.
Publicado: (2021)

Managing Substance Use Disorder through a Walking/Running Training Program
por: Dai, Chia-Liang, et al.
Publicado: (2020)

T‐cell immune response after mRNA SARS‐CoV‐2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies
por: Marasco, Vincenzo, et al.
Publicado: (2021)

Decisiones financieras
por: Pascale, Ricardo

Decisiones inteligentes : guía práctica para tomar mejores decisiones /
por: Hammond, John S., 1937-
Publicado: (1999)

Prognostic Impact of Immunohistochemical p53 Expression in Bone Marrow Biopsy in Higher Risk MDS: a Pilot Study
por: Molteni, Alfredo, et al.
Publicado: (2019)

Decisiones efectivas : guía práctica
por: Drummond, Richard Henry

Toma de decisiones financieras : contabilidad de decisiones
por: Perdomo Moreno, Abraham
Publicado: (1993)

Tomar decisiones difíciles /
por: León, Orfelio G.
Publicado: (2001)

Toma de decisiones
Publicado: (1979)

Decisiones optimas financieras
por: Robicheck, Alexander
Publicado: (1972)

Toma de decisiones /
Publicado: (1979)

Decisiones óptimas financieras /
por: Robichek, Alexander A.
Publicado: (1968)

Decisiones económicas : análisis y proyectos /
por: Fabrycky, W. J. (Wolter J.), 1932-
Publicado: (1980)

Methodological framework for radiomics applications in Hodgkin’s lymphoma
por: Sollini, Martina, et al.
Publicado: (2020)

Decisiones políticas : ¿problemática en el derecho parlamentario?
por: Esparza Martínez, Bernardino
Publicado: (2009)

The Gamow-Teller decay of $^{105}$Sn to three-particle states in $^{105}$In
por: Pfützner, M, et al.
Publicado: (1994)

Cannot write session to /tmp/vufind_sessions/sess_slqg23mgbn163delfhrg7em5q7